Please login to the form below

Tyverb

This page shows the latest Tyverb news and features for those working in and with pharma, biotech and healthcare.

Pfizer’s first-in-class breast cancer therapy wins EU licence

A number of metastatic breast cancer treatments have been rejected by the UK cost-effectiveness watchdog over the last few years, including GlaxoSmithKline's Tyverb (lapatinib) and Roche's Herceptin (trastuzumab),

Latest news

Oncology directions

For advanced breast cancer, Novartis's newly acquired breast cancer drug Tyverb (lapatinib) scores five, but there are four drugs that score three or less, including Eisai's breast cancer medicine
Novartis and GSK complete oncology and vaccines swap

Details of the asset swap were first revealed last April. Novartis claims ownership of several marketed products - including kidney cancer therapy Votrient (pazopanib) and Tyverb (lapatinib) for breast cancer - and also
England's Cancer Drugs Fund: Fixing a broken system

eribulin), GSK's Tyverb (lapatinib) and Novartis' Afinitor (everolimus)), were to be de-listed. ... GlaxoSmithKline's Tyverb (lapatinib):. treatment of advanced breast cancer. GlaxoSmithKline's Arzerra (ofatumumab):.
Pharma condemns Cancer Drugs Fund cuts

GSK. Arzerra (ofatumumab). Chronic lymphocytic leukaemia. Tyverb (lapatinib). Breast cancer. Votrient (pazopanib).
NHS names drugs to be re-evaluated for Cancer Drugs Fund

Chronic lymphocytic leukaemia. GlaxoSmithKline. Arzerra (ofatumumab) . Chronic lymphocytic leukaemia. Tyverb (lapatinib).

More from news
Approximately 3 fully matching, plus 26 partially matching documents found.

Latest appointments

GSK's oncology president joins NuCana board

During this time he has worked on major cancer products, such as Tykerb/Tyverb and Mekinist.

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Freelance AM/ AD Healthcare Advertising: £350-400 depending on experience

PRINCIPAL MEDICAL WRITER > ETL - LONDON / NEW YORK/ HOME - ME...: Salary TBC

Programme/ Account Director - Healthcare PR - London: Salary TBC

Associate Director – Social Healthcare – London: HIGHLEY COMPETATIVE SALARY, BONUS &BENEFITS

Creative/ Medical Writer: Circa £35, 000 With Benefits

Chief Medical Writer, Medical Communications, London, up to £90K...: up to £90K

Health Consultant - Brand Comms: Competitive Salary

Account Manager, MedicalCommunications/ Healthcare PR: benefits

Senior Account Executive – Account Manager – Healthcare Advertis...: £32000 - £43000 Bonus Benfits

Account Manager, Medical Communications and Marketing: £30, 000 – £40, 000 benefits and bonus

Science Writer, Healthcare Advertising Agency: £40, 000 - 45, 000 DOE benefits,

Home-based Senior Medical Writer – Med Ed: Salary TBC

Senior Account Director – Healthcare Advertising – London: Salary TBC

Scientific Director – Medical Communications - New York or Remot...: $100000 - $150000

Freelance Senior Account Manager / Account Director - Healthcare...: £350-400 depending on experience

Account Director, Medical Education: Salary TBC

Science writer, Healthcare Brand Communications, London, £45-50K...: £45-50K

Home-based Medical Writer – Medical Education: Salary TBC

Account Director, Healthcare Marketing Agency: Salary TBC

Senior Digital Health Specialist – Global Agency: Salary TBC

Home based, Senior Medical Writer, Medical Communications: Excellent package

AM – Corporate Comms/ Public Affairs/ B2B – Healthcare Focus: Salary TBC

EU Head of Business Development and Client Service: Exceptional packge and bonus

Managing Director – Global Medical Writing & Scientific Exce...: £120-150K

Digital Account Director: Salary TBC

Subscribe to our email news alerts

PMHub

Add my company

Makara Health

Independent healthcare communications agency with a passion to develop inspirational ideas that create sustained and positive change. Whether it is...

Latest intelligence

50 questions for delivering an exceptional healthcare brand experience: Our 50-question brand planning checklist for healthcare ensures you deliver an exceptional experience, based on what your stakeholders want and need...
The brand strategy revolution: Introducing a new tool for developing a stakeholder-centric brand, based on the experience your patients and their HCPs want and need....
How Medisafe is using AI to improve patient adherence: Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....